Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PRF Technologies Ltd.PRFX · Entity 8440 | Director · Exec Chairman of the Board | March 18, 2026 | March 18, 2026 |
| REGENTIS BIOMATERIALS LTD.RGNT · Entity 7824 | Director · Chief Executive Officer | July 09, 2026 | July 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PRF Technologies Ltd.
Report date March 18, 2026 · Filed March 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5,400.00 · Expires 2031-02-23 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Options granted under the 2019 PainReform Option Plan. F2: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2019 PainReform Option Plan must be registered in the name of a trustee. F3: The grant date of this grant is February 23, 2021. This option grant is fully vested as of this date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.00 · Expires 2034-07-18 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: Options granted under the 2019 PainReform Option Plan. F2: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2019 PainReform Option Plan must be registered in the name of a trustee. F4: The grant date of this grant is July 18, 2024. This option grant is fully vested as of this date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.00 · Expires 2034-10-10 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F1: Options granted under the 2019 PainReform Option Plan. F2: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2019 PainReform Option Plan must be registered in the name of a trustee. F5: The grant date of this grant is October 10, 2024. This option grant is fully vested as of this date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.05 · Expires 2035-02-20 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F1: Options granted under the 2019 PainReform Option Plan. F2: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2019 PainReform Option Plan must be registered in the name of a trustee. F6: The grant date of this grant is February 20, 2025. This option grant is fully vested as of this date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $706.80 · Expires 2033-06-08 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F1: Options granted under the 2019 PainReform Option Plan. F2: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2019 PainReform Option Plan must be registered in the name of a trustee. F7: The grant date of this grant is June 8, 2023. 144 of the options were vested as of the date of appointment. The remaining 6 options will vest on June 8, 2026, subject to the Reporting Person?s continued service to the Issuer as of such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Options granted under the 2019 PainReform Option Plan.
F2: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2019 PainReform Option Plan must be registered in the name of a trustee.
F3: The grant date of this grant is February 23, 2021. This option grant is fully vested as of this date.
F4: The grant date of this grant is July 18, 2024. This option grant is fully vested as of this date.
F5: The grant date of this grant is October 10, 2024. This option grant is fully vested as of this date.
F6: The grant date of this grant is February 20, 2025. This option grant is fully vested as of this date.
F7: The grant date of this grant is June 8, 2023. 144 of the options were vested as of the date of appointment. The remaining 6 options will vest on June 8, 2026, subject to the Reporting Person?s continued service to the Issuer as of such date.
REGENTIS BIOMATERIALS LTD.
Report date July 09, 2026 · Filed July 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Warrants to purchase ordinary sharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2029-02-23 | Direct | 31,250 |
Reported balance
After 2026-07-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-09 · Grant · Acquired 31,250 · Balance 31,250 F1: This warrant was approved by the Board of Directors of the Issuer on February 23, 2026, subject to shareholder approval, which was obtained on July 9, 2026. F2: The warrants are currently exercisable and have a three year term. |
Filing footnotes · ownership attribution and instrument terms
F1: This warrant was approved by the Board of Directors of the Issuer on February 23, 2026, subject to shareholder approval, which was obtained on July 9, 2026.
F2: The warrants are currently exercisable and have a three year term.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 09, 2026 Filed Jul 13, 2026 21:05 UTC | REGENTIS BIOMATERIALS LTD. RGNT · Entity 7824 | GrantWarrants to purchase ordinary shares · Derivative | 31,250 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-077631 · ownership.xml · derivative · entry 1 GELLER EHUD · CIK 0001284386 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,250 Underlying: Ordinary Shares · 31,250 shares Expires 2029-02-23 F1 · security: This warrant was approved by the Board of Directors of the Issuer on February 23, 2026, subject to shareholder approval, which was obtained on July 9, 2026. F2 · security: The warrants are currently exercisable and have a three year term. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.